Takeda enlists Poseida in $3.6B+ nonviral gene therapy deal, though data remain years away from human studies

Max Gelman

Senior Editor

Takeda has been behind other major players in terms of cell and gene therapy development, but after announcing a collaboration with Selecta Biosciences last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda enlists Poseida in $3.6B+ nonviral gene therapy deal, though data remain years away from human studies

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry

Take­da en­lists Po­sei­da in $3.6B+ non­vi­ral gene ther­a­py deal, though da­ta re­main years away from hu­man stud­ies

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Takeda enlists Poseida in $3.6B+ nonviral gene therapy deal, though data remain years away from human studies